| Product Name | Bispecific anti-mouse PD-1 x anti-mouse VEGF-A (LALA-PG) |
|---|---|
| Product description | Bispecific anti-mouse PD-1 x anti-mouse VEGF-A (LALA-PG) is a 2+2 symmetric tetravalent bispecific structured after Ivonescimab but engineered to simultaneously target mouse programmed cell death protein 1 (PD-1, CD279) and mouse vascular endothelial growth factor A (VEGF-A) proteins. Bispecific anti-mouse PD-1 x anti-mouse VEGF-A (LALA-PG) contains the murine IgG2a constant region to reduce immunogenicity and the formation of anti-drug antibodies (ADAs) in mouse models and LALA-PG Fc-silencing mutations to abolish antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) while minimizing Fc-driven off-target toxicity. This bispecific was designed to concurrently block two key pathways involved in tumor progression and immune evasion through dual PD-1 and VEGF-A inhibition. The tetravalent structure provides four antigen-binding sites to enable cooperative binding that can leverage target proximity within the tumor microenvironment. |
| Clonality | Monoclonal |
| Isotype | mouse IgG2a (LALA-PG)-scFv, κ |
| Reactivity | Mouse |
| Endotoxin | ≤0.5EU/mg (≤0.0005EU/μg)Determined by LAL assay |
| Purification | Protein G |
| Purity | ≥95% Determined by SDS-PAGE |
| Application | in vivo functional assays in vitro functional assays ELISA |
| Form | Liquid |
| Formulation | PBS, pH 7.0 Contains no stabilizers or preservatives |
| Storage | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
